BNTX (BioNTech SE) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 04, 2026)


BNTX BioNTech SE BNTX
62 GF Score
Price $97.55
GF Value $88.05
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioNTech SE Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

BioNTech SE's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

BNTX vs INCY, INSM, ROIV: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, BioNTech SE's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Margin of Safety % (DCF Dividends Based) falls into.


BNTX
62GF Score
BioNTech SE BNTX
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioNTech SE (BNTX) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of $97.55 is trading 10.8% above its estimated GF Value™ of $88.05. GuruFocus considers BioNTech SE to be Modestly Overvalued.

Key valuation signals for BNTX:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $88.05 vs. price of $97.55 (10.8% above fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score

Get the complete analysis for BNTX

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$97.55
Price
$88.05
GF Value